



ALLE0014-103 (17355CIP3)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Lance E. Steward, et al.

Serial No.: 10/757,077

Filed: January 14, 2004

Art Unit: Not Yet

Assigned

FOR: CLOSTRIDIAL NEUROTOXIN COMPOSITIONS
AND MODIFIED CLOSTRIDIAL NEUROTOXINS

Examiner: Not Yet

Assigned

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

**STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE
WITH 37 CFR §§ 1.821 THROUGH 1.825**

I hereby state, in accordance with the requirements of 37 C.F.R. §1.821(f), that the contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR §1.821(c) and (e), respectively are the same.

I hereby state that the submission filed in accordance with 37 CFR §1.821(g) does not include new matter.

I hereby state that the submission filed in accordance with 37 CFR §1.821(h) does not include new matter or go beyond the disclosure in the international application as filed.

I hereby state that the amendments, made in accordance with 37 CFR §1.825(a), included in the substitute sheet(s) of the Sequence Listing are supported in the application, as filed. I hereby state that the substitute sheet(s) of the Sequence Listing does (do) not include new matter.

I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 CFR §1.825(b), is the same as the amended Sequence Listing.



I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 CFR §1.825(d), contains identical data to that originally filed.

Respectfully submitted,

David A. Sadewasser
David A. Sadewasser
Registration No. 55,587

Date: June 17, 2004

COZEN O'CONNOR, P.C.
1900 Market Street – 5th Floor
Philadelphia, PA 19103-3508
Telephone: (215) 665-2000